Skip to main content
Premium Trial:

Request an Annual Quote

Ardais, Pioneer Hi-Bred, NanoInk

Premium

Ardais Takes in $14M Series C

Ardais of Lexington, Mass., closed a $14 million Series C round of venture capital financing in December. The five-year-old firm, which serves as a repository for human tissue for research, took its last round of financing in March 2001 and was valued at $72 million then. Investors in the current round include CIT Group, Pequot Capital, Advanced Technology Ventures, Advent International, Bessemer Venture Partners, and The Kaufmann Fund.

 

Pioneer Hi-Bred Links With Agilent

Researchers at Pioneer Hi-Bred International Inc., a subsidiary of DuPont headquartered in Des Moines, Iowa, will use Agilent microarrays and Rosetta Resolver informatics systems in their plant genomics research, Agilent announced this week. Pioneer Hi-Bred will examine gene expression during specific stages of a plant’s life.

 

NanoInk collects $6 Million Investment

NanoInk of Chicago, a Northwestern University spinoff developing a nanolithography technology marketed as the direct-write dip-pen writer, has closed on a $6 million second round of financing led by Lurie Investment Fund. The company said the funding will accelerate the first-quarter release of the product.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.